Gastro-enteropancreatic Neuroendocrine TumorLUNET-2NCT07653126
A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
An observational study of Gastro-enteropancreatic Neuroendocrine Tumor, run by Novartis Pharmaceuticals at 7 sites in Germany.
Trial summary
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastro-enteropancreatic Neuroendocrine Tumor
- How many people
- 117 participants
- Where
- 7 sitesGermany
- Study dates
- 3 Apr 2023to 29 Sep 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult GEP-NET patients in Germany who received their first cycle of primary PRRT between 01 July 2020 and 30 June 2021.
Who may be able to join
- Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin [CUP], any Grade).
- Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.
Who cannot join
- Received a combination of PRRT with chemotherapy.
- Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
Germany7 sites
Novartis Investigative Site
Essen
Novartis Investigative Site
Heidelberg
Novartis Investigative Site
München
Novartis Investigative Site
Rostock
Novartis Investigative Site
Stuttgart
Novartis Investigative Site
Tübingen
Novartis Investigative Site
Würzburg
About this study
Official title: Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
- Keywords
- Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumors, GEP-NET, Peptide Receptor Radionuclide Therapy, PRRT, Lutetium-177, 177Lu-DOTATATE, Real World, Germany
- Medical subject headings
- Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| PRRT Cohort | Adult GEP-NET patients who received PRRT in German routine care. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Baseline Demographics
Measured: Baseline
Number of Patients by Tumor Status
Measured: Baseline
Duration Between Initial Diagnosis and Initiation of Primary PRRT
Measured: Baseline
Number of Patients by PRRT Line of Therapy
Measured: Approximately 1 year
Number of Patients by Type of PRRT Received
Measured: Approximately 1 year
PRRT Dosage
Measured: Approximately 1 year
Number of Patients by Treatment Interval
Measured: Approximately 1 year
Number of Patients by Co-medication
Measured: Approximately 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start3 Apr 2023
- Primary completion29 Sep 2023
- Study completion29 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastro-enteropancreatic Neuroendocrine TumorStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 117 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07653126
- Sponsor's protocol ID
- CAAA601A1DE01
- Acronym
- LUNET-2
- Status last verified
- Jun 2026
- First submitted
- 12 Jun 2026
- Last updated
- 17 Jun 2026
- Results posted
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)
- ClinicalTrials.gov ID
- NCT07653126
- Acronym / sponsor ID
- LUNET-2 / CAAA601A1DE01
- Keywords
- Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumors, GEP-NET, Peptide Receptor Radionuclide Therapy, PRRT, Lutetium-177, 177Lu-DOTATATE, Real World
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 117 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 3 Apr 2023 (actual)
- Primary completion
- 29 Sep 2023 (actual)
- Study completion
- 29 Sep 2023 (actual)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PRRT Cohort | – | –Adult GEP-NET patients who received PRRT in German routine care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult GEP-NET patients in Germany who received their first cycle of primary PRRT between 01 July 2020 and 30 June 2021.
Key inclusion criteria (2 listed)
- Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin [CUP], any Grade).
- Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.
Key exclusion criteria (2 listed)
- Received a combination of PRRT with chemotherapy.
- Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Baseline Demographics
Time frame: Baseline
Number of Patients by Tumor Status
Time frame: Baseline
Duration Between Initial Diagnosis and Initiation of Primary PRRT
Time frame: Baseline
Number of Patients by PRRT Line of Therapy
Time frame: Approximately 1 year
Number of Patients by Type of PRRT Received
Time frame: Approximately 1 year
PRRT Dosage
Time frame: Approximately 1 year
Number of Patients by Treatment Interval
Time frame: Approximately 1 year
Number of Patients by Co-medication
Time frame: Approximately 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Gastro-enteropancreatic Neuroendocrine Tumor
RecruitingPhase 2
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2
Enrolling by invitationObservational study
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases
Neuroendocrine Tumors
RecruitingPhase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Not yet recruitingPhase 3
TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS
Gastroenteropancreatic Neuroendocrine Tumors
RecruitingPhase 1
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Somatostatin Receptor Positive, NETs
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastro-enteropancreatic Neuroendocrine Tumor, run by Novartis Pharmaceuticals at 7 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Baseline Demographics (time frame: Baseline). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.